07:00 , Jun 6, 2016 |  BioCentury  |  Finance

Extra stuffing

Inbound interest from a strategic investor and a basket of liquidity events from LSP's prior fund helped the firm close its newest fund at $280 million, which was the hard cap. The result of LSP...
07:00 , May 25, 2015 |  BioCentury  |  Finance

Innovation underfed

Stephen Hansen, Associate Editor   Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone...
01:15 , May 6, 2015 |  BC Extra  |  Company News

Management tracks

Oncology company Cleveland BioLabs Inc. (NASDAQ:CBLI) named Langdon Miller president and CMO. Miller was VP of clinical research in oncology at Gilead Sciences Inc. (NASDAQ:GILD) after it acquired Calistoga Pharmaceuticals Inc. , where he had...
02:57 , Oct 2, 2014 |  BC Extra  |  Financial News

LSP raises EUR 80M toward Fund 5

LSP-Life Sciences Partners has raised the first EUR 80 million ($101.4 million) of a planned EUR 150 million fund. The firm said it intends to invest its new Fund 5 in 10-15 private companies with...
07:00 , Mar 31, 2014 |  BioCentury  |  Finance

LSP's steady hand

When LSP-Life Sciences Partners launches a new healthcare venture fund next year it will stick to a strategy that has yielded 12 exits in the past 18 months - early stage, European drug development companies....
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

Activaero, Vectura deal

Pulmonary play Vectura Group is acquiring drug delivery company Activaero for €130 million ($180.6 million). The amount comprises €45 million ($62.5 million) up front in cash and €50 million ($69.5 million) in new Vectura shares,...
07:00 , Mar 17, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) was off $0.16 to $15.11 last week after submitting an MAA to EMA for Zerenex ferric citrate to treat hyperphosphatemia in dialysis dependent and non-dialysis dependent patients with chronic...
23:39 , Mar 13, 2014 |  BC Extra  |  Company News

Vectura acquiring Activaero, raises L52 million in placing

Pulmonary play Vectura Group plc (LSE:VEC) is acquiring drug delivery company Activaero GmbH (Gemuenden, Germany) for EUR 130 million ($180.6 million). The amount comprises EUR 45 million ($62.5 million) up front in cash and EUR...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Company News

Activaero management update

Activaero GmbH , Gemuenden, Germany   Business: Drug delivery   Hired: Ulrich Dauer as chief strategy officer, formerly CEO of 4SC AG  ...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Activaero, Chiesi deal

The companies partnered to evaluate a drug-device combination product using Activaero's Flow and Volume Controlled Inhalation Technology (FAVORITE) and Chiesi's Bethkis inhaled tobramycin solution to treat cystic fibrosis (CF). The partners expect to complete in...